Compliance with treatment in adult patients with cystic fibrosis

S P Conway, M N Pond, T Hamnett, A Watson

Abstract

Background – Patients with chronic disease comply with about 50% of their treatment. The complex and time consuming daily drug regimens needed in the care of adult patients with cystic fibrosis encourage non-compliance with prescribed treatments. Understanding the reasons for, and the extent of, non-compliance is essential for a realistic appraisal of the patient’s condition and sensible planning of future treatment programmes.

Methods – Patients were invited to complete a questionnaire which asked about their compliance with daily treatment. The data were used to calculate a compliance score, the percentage of prescribed treatment taken, and to examine patient attitudes to each individual prescription. An assessment score derived from consultant, cystic fibrosis research fellow, specialist nurse, and physiotherapist ratings of patient compliance was compared with the compliance score. Both scores were correlated with patient characteristics and disease severity, and the compliance score was also correlated with the patient’s knowledge of cystic fibrosis.

Results – More than half the patients claimed to take more than 80% of their treatments. Compliance with individual treatments varied according to their perceived unpleasantness and degree of infringement on daily activities. The most common reason given for omitting treatment was forgetfulness. Professional carers were poor judges of patient compliance. There was no correlation between compliance and patients’ sociodemographic characteristics or their knowledge about cystic fibrosis.

Conclusions – Non-compliance is universal and should be recognised as normal behaviour. There are no reliable criteria for predicting any patient’s level of compliance. Treatment protocols should be planned around individual patient’s requirements, modifying treatment ideals where necessary according to the exigency and pattern of that patient’s lifestyle.

(Thorax 1996;51:29–33)

Keywords: adult cystic fibrosis, compliance.

Compliance with appropriate and effective treatment programmes for cystic fibrosis will improve a patient’s quality of life and prolong survival. The physician is, however, likely to overestimate his patients’ adherence to therapeutic regimens. There is general agreement that only one third of patients adequately comply, one third partially comply, and one third fail to comply, so that overall compliance rates are about 50%. In chronic illness, coping mechanisms of denial and minimisation and attempts to assume “normality” and reduce anxiety can divert patients from optimal treatment. In order to change patients’ behaviour we must recognise that a degree of non-compliance is normal, attempt to quantify it, and understand the likely factors that produce such behaviour in the individual patient. For patients receiving multiple treatments we must examine compliance with each individual treatment. This study was undertaken in an attempt to assess the degree of, and understand the nature of, compliance in a large adult population with cystic fibrosis.

Methods

Patients were asked to complete a questionnaire on daily compliance with 12 different commonly prescribed treatments; oral and nebulised antibiotics, vitamin supplements (A, D, and E), inhaled and oral corticosteroids, inhaled bronchodilators, insulin, glibenclamide, dietary supplements, pancreatic enzyme supplements, and physiotherapy. Patients prescribed any of the above on a daily basis indicated whether they adhered to the treatment regimen “every day or almost every day” (good compliance), “about 3–5 days a week” (moderate compliance), “less than 3 days a week” or “never” (poor compliance). For pancreatic enzyme supplements the questions were similarly phrased to show compliance with enzyme prescriptions for meals and snacks. Respondents were asked to indicate if any of the following reasons for non-adherence to prescribed treatments applied:

(1) I’m not sure why I should be taking it;
(2) I don’t feel it makes any difference;
(3) I tend to forget;
(4) it takes a lot of effort/time to take it;
(5) it makes me feel worse;
(6) it tastes awful/makes the room smell (nebulised antibiotics only);
(7) it’s embarrassing (pancreatic enzyme supplements and physiotherapy only);
(8) no time in the morning/too tired at night/ I do exercise instead (physiotherapy only);
(9) any other reasons.

Respondents could give more than one reason for non-compliance with any treatment. The
questionnaire was explained individually to each patient. Respondents were given the option to complete the questionnaire anonymously.

Basic data were collected on each patient to provide a patient profile:

1. age and sex;
2. employment status;
3. social class;
4. time as an inpatient during the preceding year;
5. number of inpatient treatments during the preceding year;
6. average % weight/height and forced expiratory volume in one second (FEV₁) during the preceding year;
7. Chrispin-Norman score,* Shwachman–Kulczycki score¹ (numerical scores, the former an assessment of the chest radiograph and the latter an overall clinical assessment, with higher and lower scores representing increasing disease severity, respectively);
8. disease severity scored on a visual analogue scale by both respondent and doctor (SPC). The difference between the patient’s and the doctor’s score was analysed by the Wilcoxon signed rank test.

Data from (5) to (8) were used to calculate an overall disease severity score. A compliance score estimating the percentage of prescribed treatment taken was calculated from the questionnaire answers. The consultant, registrar, physiotherapist, and specialist nurse were each asked to estimate and rate in quartiles compliance for all patients without reference to the data. Correlations between these quartiles and those for the compliance score were measured by Goodman and Kruskal's gamma. Spearman rank correlation was used to assess any association between the assessment score, based on the average of the four carers' assessments, and the compliance score. Agreement between the physiotherapist's prediction of patient compliance and patients' reported compliance with physiotherapy was assessed by dividing predictions and responses into two categories. Good compliance was represented by physiotherapist allocation of patients to the highest two quartiles and patients reporting adherence to the physiotherapy regimen on at least five days a week.

The compliance score and the assessment score were correlated with patient characteristics and disease severity using the Wilcoxon-Mann-Whitney U test for sex, the Kruskal-Wallis one way analysis of variance for employment and social class, and by testing significance of the Spearman rank correlation coefficient for the other variables. Any association between questionnaire derived compliance scores, where respondents gave their name, and respondents' knowledge about cystic fibrosis determined from a multiple choice questionnaire, was assessed by testing the significance of the Spearman rank correlation coefficient.

Results
Eighty (88%) of 91 patients responded to the questionnaire. Seventy six (95%) gave their names, of whom 40 were women. The median patient age was 22 years (range 14–40). The median number of prescriptions per patient was seven (range 2–11).

Patient self rating of disease severity on a visual analogue scale of 0–10 was shifted to the left (less severe) when compared with physician (SPC) rating (p = 0.001). Compliance with therapy varied with the different treatments assessed (table 1).

Some reasons given for non-compliance were specific to certain therapies – for example, "embarrassment" (pancreatic enzymes and physiotherapy), "do exercise instead" (physiotherapy), and "it tastes awful" (nebulised antibiotics and inhaled steroids). Other reasons were applicable to all 12 prescriptions (table 2). The most common reason given for omitting treatment was "I tend to forget!", which accounted for 66% of missed vitamin supplements, 64% of missed oral antibiotics, 55% of missed pancreatic enzyme supplements, 50% of missed inhaled corticosteroids, and 29% of missed dietary supplements. The degree of effort and time needed for adherence to prescriptions for nebulised antibiotics, dietary supplements and inhaled bronchodilators accounted for 60%, 41%, and 41% of missed doses, respectively. Respondents gave more than twice as many reasons for not doing physiotherapy as for any other treatment studied. The major reasons for omitting physiotherapy were the time and commitment it
Compliance with treatment in adult cystic fibrosis

Table 3: Correlations between different carers’ assessments of patient compliance, and between carers’ assessment and patients’ compliance score

<table>
<thead>
<tr>
<th>Carer Type</th>
<th>Registrar</th>
<th>Physiotherapist</th>
<th>Nurse</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consultant</td>
<td>0.57</td>
<td>0.72</td>
<td>0.58</td>
<td>0.09</td>
</tr>
<tr>
<td>Registrar</td>
<td>0.63</td>
<td>0.55</td>
<td>0.22</td>
<td></td>
</tr>
<tr>
<td>Physiotherapist</td>
<td>0.62</td>
<td>0.37</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specialist nurse</td>
<td>0.20</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4: Relationship of patients’ characteristics to questionnaire compliance score and carers’ assessment score (significance = higher compliance)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Compliance score</th>
<th>Carers’ score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>p&lt;0.05 (younger)</td>
<td>NS</td>
</tr>
<tr>
<td>Sex</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Employed</td>
<td>NS</td>
<td>p&lt;0.05†</td>
</tr>
<tr>
<td>Social class</td>
<td>NS</td>
<td>p&lt;0.001 (higher)</td>
</tr>
<tr>
<td>Number of admissions</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>% weight/height</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>% predicted FEV,</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Severity score</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

†Employment categories in descending order of median compliance score were: student/housewife, part-time, full-time, unemployed.

Discussion

Patient compliance, “the extent to which a person’s behaviour (in terms of taking medication, following diets, or executing lifestyle changes) coincides with medical or health advice”, is complex, inconsistent, and poorly understood. The degree of compliance across all medical prescriptions lies between 30% and 70%, with approximately half of patients with chronic disease showing non-compliance. Because of the chronicity of cystic fibrosis and the necessity for multiple daily medications (the median number of daily prescriptions per patient in this study was seven), patients are likely to have a high degree of non-compliance. Moreover, the demands of cystic fibrosis have to be balanced with those of work, family, and other relationships. This becomes more difficult in adolescence and adult life, compliance tending to decrease with increasing age. Young adults with cystic fibrosis are generally well adjusted at school, work, and home but may experience depression and anxiety when ill, and deny both present symptoms and eventual outcome when well. Denial is found in all chronic illness groups, and tends to increase with age to facilitate emotional adjustment to adult life. Our own adult respondents saw themselves as less severely ill than did their doctor, a common misperception of personal health status. Coping mechanisms involving denial and minimisation will tend to subvert optimal treatment regimens by encouraging a rejection of clinical advice. These are responses that must be taken into account when planning overall treatment.

Self-assessment may overestimate compliance by up to 20% but agrees well with more objective assessments when done in a non-judgemental and non-threatening way. Overall compliance in this study was good with over half the respondents claiming to take more than 80% of their treatments. Others report similar results. The greater compliance found in the cystic fibrosis series in comparison with other chronic diseases probably reflects patient focus on the short term benefits of treatment and the immediacy of unpleasant symptoms consequent on non-compliance. The much greater compliance shown by our own respondents with diabetic medication and pancreatic enzyme supplements with meals, as compared with that with nebulised antibiotics, dietary supplements, physiotherapy, and enzyme supplements with snacks, probably reflects this outlook.

The natural tendency to forget was the most common reason given for omitting treatment (34% of responses). The second most common reason for non-compliance was the commitment in effort and time demanded by the treatment regimen (31% of responses). The least difficult programmes and those requiring the least alteration to lifestyle will tend to be favoured. Physiotherapy, dietary supplements, and nebulised therapies are low priorities for most patients as they require the most planning and interfere the most with daily life. The third most common reason given by patients was a preference for exercise instead of physiotherapy. This suggests that many patients did not perceive chest physiotherapy as necessary for their treatment. However, the majority of patients (81%) also reported attending chest physiotherapy regularly. This suggests that the decision to attend physiotherapy is made at the time of the appointment, and is made independently of the patient’s ability to comply with the treatment regimen. The second most common reason given for non-compliance was the need for treatment. This suggests that the need for treatment is a significant factor in determining compliance. The third most common reason given by patients was the perception of the treatment as unnecessary. This suggests that patients may not understand the importance of their treatment, or may feel that the treatment is not effective.

The influence of patient characteristics on both the compliance score and the assessment score are shown in table 4. When considering the five most commonly prescribed treatments, patients with more outpatient visits showed greater compliance (p<0.05). The significance of the relationship seems to depend on a few very frequent attenders with good compliance and a few very poor compliers with relatively few attendances. Taking 85% compliance with the five treatments as a cut-off point (dividing the patients into equal halves), the more complaint subjects had more outpatient visits (p = 0.01). Correlation between respondents’ knowledge of cystic fibrosis determined by a multiple choice questionnaire and the compliance questionnaire score was not significant.

The demands (44%), a preference for exercise instead (27%), and a perception that it makes no difference (13%) of nineteen patients only did chest physiotherapy "when my chest is bad". Two patients had very low compliance scores of 10% and 28%. The scores in the remainder were: 50–59% (three patients), 60–69% (four patients), 70–79% (13 patients), 80–89% (27 patients), 90–99% (23 patients), and 100% (eight patients). Correlations between carers’ assessments of patients’ compliance, rated in quartiles, and between these assessments and the quartiles for the questionnaire derived compliance scores, are shown in table 3. The Spearman rank correlation coefficient between the assessment score, based on the average of the four carers’ assessments and the questionnaire score was 0.31. Analysis of the physiotherapist’s prediction of patient compliance and reported compliance with physiotherapy showed agreement in 67% of cases.

The influence of patient characteristics on both the compliance score and the assessment score are shown in table 4. When considering the five most commonly prescribed treatments, patients with more outpatient visits showed greater compliance (p<0.05). The significance of the relationship seems to depend on a few very frequent attenders with good compliance and a few very poor compliers with relatively few attendances. Taking 85% compliance with the five treatments as a cut-off point (dividing the patients into equal halves), the more compliant subjects had more outpatient visits (p = 0.01). Correlation between respondents’ knowledge of cystic fibrosis determined by a multiple choice questionnaire and the compliance questionnaire score was not significant.

The natural tendency to forget was the most common reason given for omitting treatment (34% of responses). The second most common reason for non-compliance was the commitment in effort and time demanded by the treatment regimen (31% of responses). The least difficult programmes and those requiring the least alteration to lifestyle will tend to be favoured. Physiotherapy, dietary supplements, and nebulised therapies are low priorities for most patients as they require the most planning and interfere the most with daily life. The third most common reason given

Downloaded from http://thorax.bmj.com/ on June 21, 2017 - Published by group.bmj.com
for omitting therapy was a perception that the treatment did not make any difference (13% of responses) – for example, 19 patients only did chest physiotherapy during a respiratory exacerbation, and seven only took inhaled bronchodilators when symptomatic. Given the above plethora of influences governing patient action it is not surprising that compliance varies with each of the treatments evaluated.9 22

The dislike of, and non-compliance with, physiotherapy is universal, with most studies, as ours, reporting approximately only half of patients with good compliance.22 29 The 80 respondents gave 111 reasons for not doing physiotherapy, 49 relating to the time and effort needed, and 30 citing a preference for exercise, an activity with good peer group acceptability.

On only three occasions was “I’m not sure why I should be taking the treatment” given as the reason for non-compliance. Physicians and allied professionals caring for adults with cystic fibrosis can testify to the high degree of patient knowledge about their medication. There was no significant correlation between patients’ compliance and their knowledge about cystic fibrosis in general. We would argue that education alone10 29 30 will not be enough to improve compliance.31

The assessment scores of patient compliance showed good concordance but little or no correlation with the patient’s questionnaire compliance score. This agrees with most,14 but not all,15 26 previous studies. Doctors, physiotherapists, and nurses must be aware of the likelihood that they will overestimate compliance and may only become aware of this when medical complications show, and further irreversible lung damage has occurred. Cystic fibrosis carers may be better at assessing patient compliance within their own specialised area. The physiotherapist’s assessment showed better agreement with patients’ compliance with physiotherapy than with patients’ compliance with treatment in general.

The subjective views of the four carers may also reflect personal value judgements, with students, the employed, and the higher social classes being seen as most compliant. The questionnaire score showed no effect on compliance of any sociodemographic factor, or of any marker of disease severity, a result consistent with previous work.9 20 25 30 This underlines the unreliability of predicting individual patient compliance.

How might we improve patient compliance? Physiotherapy is our most prescribed therapy and yet had the second lowest compliance rate. Patients struggling to adhere to a particular physiotherapy regimen might find alternative methods less onerous. Full use should be made of educational aids such as models of the bronchial tree and lungs (Adam Rouilly, manufacturers) to underline the rationale of physical treatment. Patients with generally poor compliance might benefit from small group interactive sessions, gaining from peer support and the knowledge that others have similar difficulties. Time management skills might help those who cannot fit their therapies into their routine lives. With adequate resources, greater support could be given in the home by the cystic fibrosis specialist nurse and community physiotherapist. Self-monitoring by respiratory function tests, recording of weight, and sputum volume, should be encouraged both as a feedback to patients of the efficacy of their self-treatment, and as an indicator and a way to increase the intensity of their treatment.

It is axiomatic that an attempt to assess patient adherence to treatment regimens should be made at each contact between doctor and patient, with encouragement within a secure and friendly relationship10 13 17 to discuss all aspects of the disease as patients grow into adolescence.22 Emphasis on the need for compliance must be accompanied by information that gives hope. We must convince patients that their actions in taking treatment make a difference, recognise that there is no single treatment regimen for all patients, simplify treatment, and to make patients closely monitor, extensive follow up and adequate supervision, and always try to be non-judgmental, accepting that non-compliance is the norm.5

The data showed a significant association between the frequency of outpatient attendance and compliance when the five most commonly prescribed therapies were considered. Statistics cannot demonstrate cause and effect. More compliant patients may attend outpatients more regularly, or patients may be more compliant as a result of more frequent outpatient attendance. Yet we hypothesise that the significance shown by patients who attended outpatients more frequently reflects a positive outcome from more doctor-patient contacts during which time the above principles are espoused. This may in turn be partly responsible for the improved clinical status seen in patients with more frequent hospital contacts.32

14 Rapoff MA, Christopherson ER. Compliance of paediatric patients with medical regimens: a review and evaluation.
Compliance with treatment in adult cystic fibrosis


Compliance with treatment in adult patients with cystic fibrosis.

S. P. Conway, M. N. Pond, T. Hamnett and A. Watson

Thorax 1996 51: 29-33
doi: 10.1136/thx.51.1.29

Updated information and services can be found at:
http://thorax.bmj.com/content/51/1/29

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/